Feature | March 16, 2015

New Research Shows PCI Benefits STEMI Patients Even After 12 Hours

Late-presenting patients show same results as early presenters

Minneapolis Heart Institute Foundation, PCI, STEMI, late presenters

March 16, 2015 — New research from the Minneapolis Heart Institute Foundation (MHIF) finds that percutaneous coronary intervention for heart attacks can still be beneficial for patients who get to their more than 12 hours after their chest pain has started. Timothy Henry, M.D., lead MHIF researcher and director of cardiology at Cedars-Sinai Medical Center in Los Angeles, presented the study results at the 2015 American College of Cardiology (ACC) conference in San Diego.

Almost 250,000 Americans experience ST-elevated myocardial infarction (STEMI), the deadliest form of heart attack, each year. Many of these patients are treated with percutaneous coronary intervention (PCI, or coronary artery stenting) within 90 minutes of getting to a medical center — a guideline recommended by the American Heart Association. But treatment guidelines have been less clear for patients who get to a medical center late — more than 12 hours after their chest pain has started. “Despite previous studies showing PCI improves survival for these late presenters,” said Henry, “management of these patients continues to be controversial.”

To further study the impact of PCI on STEMI patients who receive later treatment, Henry and a team of MHIF researchers examined prospective data from 3,157 patients in the Level 1 regional STEMI program at the Minneapolis Heart Institute at Abbott Northwestern Hospital from March 2003 to March 2014. They placed the patients into three groups: those that arrived at a medical center within 6 hours of chest pain starting (“early presenters”), those arriving within 6–12 hours, and those arriving 12–24 hours after the start of pain (“late presenters”).

The death rate (in-hospital, at 30 days, and at 1 year) and length of hospital stay for late presenters (6.7 percent of patients) was similar to that of early presenters. “Our research supports the use of primary PCI in late presenters,” stated Henry. “Although the door to balloon time was longer for late presenters, the clinical benefits of PCI were similar to those who received earlier treatment.”

For more information: www.mplsheart.org

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init